期刊文献+

绝经妇女骨丢失率及骨吸收指标的变化 被引量:4

The Temporal Changes of Bone Loss Rate and Bone Resorptive Biochemical Markers in Postmenopausal Women
暂未订购
导出
摘要 目的:了解南京市区妇女骨丢失率及骨吸收指标与绝经时间的关系,为早期防治骨质疏松提供依据。方法:随机测定576例妇女骨吸收指标尿吡啶酚(Pyr)浓度,其中233例同时测量腰椎2~4、左髋部股骨颈骨密度。按中青年、围绝经期、绝经早期、绝经晚期分4组。结果:①腰椎2~4、股骨颈骨密度年下降率:围绝经期与绝经前相似为0.6%、0.5%;绝经早期为2.3%、0.9%;绝经晚期为1.0%、1.6%。②围绝经期、绝经早期及绝经晚期与中青年尿Pyr/Cr(肌酐)比较均升高,差异有显著性(P<0.01),后3组间比较差异无显著性(P>0.05)。各组骨质疏松伴发率分别为0、2.2%、22.8%、67.6%。③围绝经期及其后妇女中,骨量正常、骨量减少及骨质疏松3组间尿Pyr/Cr比较差异无显著性(P>0.05)。结论:①围绝经期及其后妇女骨吸收指标处于稳定的高水平。②围绝经期骨丢失率与绝经前相当;绝经早期妇女以松质骨为主的腰椎骨量丢失最快,以后下降处于稳定状态;随年龄增长,股骨颈骨量年丢失率逐渐增加。③骨密度与骨吸收指标之间无相关关系。 Objective:To probe the relation among bone loss rate, bone-resorptive biochemical marker and the time of menopause in Nanjing women. Methods:Forty young healthy women (mean age 31.2 years), 120 peri-men opause women (mean age 48.3 years), 172 recent postmenopausal women (the menopause per iod≤5 years) and 244 late postmenopausal women (the menopause periods>5 years) we re enrolled in this study. The urinary pyridinoline concentrations (Pyr/Cr), bon e-resorptive biochemical marker, of all the 576 cases were measured by EIA, the bone mineral density (BMD) of L2~4 and femoral neck (FN) in 233/576 case s were determined by dual energy X-ray absorptiometry (DEXA). Results:①The reduction of BMD of L2~4 and FN were 0.6% and 0.5% in perimenopau sal women, 2.3% and 0.9% in recent postmenopausal women, 1.0% and 1.6% in late postmenopausal woman respectively. ②The urinary Pyr/Cr of perimenopausal, earl y postmenopausal and late postmenopausal women were similar (P>{0.05)}, b ut all higher than that of young women respectively (all, P<0.01). ③In per imenop ausal, early and late postmenopausal women, the urinary Pyr/Cr among the women w ith normal BMD, osteopenia and osteoporosis were no significantly different (P >0.05). Conclusion:①The bone loss of lumbar veterbrae in recent po stmenopausal women in the most, and it declined steady in later, while that of FN gradually decreased with aging. ②The bone resorption is constantly increased after perimenopause. ③There is no closely relation between the urinary Pyr/Cr and BMD.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2002年第2期141-143,共3页 Journal of Nanjing Medical University(Natural Sciences)
关键词 绝经妇女 骨密度 吡啶酚 骨丢失率 骨吸收指标 骨质疏松 防治 postmenopause women bone mineral density pyridinoline
  • 相关文献

参考文献2

共引文献21

同被引文献42

  • 1胡素敏,毛雪瑛,柴之芳,高学敏,张建军,欧阳宏,王洪飞,黄宇营.用核分析技术研究骨质疏松大鼠骨中无机元素的丢失与恢复[J].中国中西医结合杂志,2005,25(S1):129-132. 被引量:1
  • 2崔伟,史之祯,刘成林.模拟失重大鼠骨矿盐再分布与骨力学性能降低[J].中国骨质疏松杂志,1998,4(2):9-11. 被引量:7
  • 3张清学,邝健全.绝经后妇女应用激素治疗的利弊[J].新医学,2005,36(8):491-492. 被引量:3
  • 4Liberman UA,Weiss SR,Broll J,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis [J]. N Engl J Med, 1995,333(22) : 1437-1443.
  • 5Bone HG, Hosking D,Devogelaer JP,et al. Ten years' experience with alendronate for osteoporosis in post- menopausal women [J]. N Engl J Med, 2004,350 (12) : 1189-1199.
  • 6Ensrud KE,Barrett-Connor EL,Schwartz A,et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD:results from the fracture intervention trial long-term extension [J]. J Bone Miner Res,2004,19(8) : 1259-1269.
  • 7Papapoulos SE, Quandt SA, Liberman UA,et al. Meta- analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women[J]. Osteoporos Int, 2005,16(2) : 468-474.
  • 8Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension(FLEX) : a randomized trial [ J ]. JAMA, 2006,296 (24) : 2927-2938.
  • 9Iqbal MM. Osteoporosis: Epidemiology, diagnosis, and treatment[J]. South Med J,2000,93(1):2-18.
  • 10Miller PD,McClung MR,Macovei L,et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1- year resuhs from the mobile study[J]. J Bone Miner Res, 2005,20(8) : 1315-1322.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部